ClinicalTrials.gg
WithdrawnNCT05504187Updated Nov 9, 2026

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

A Phase 2 interventional study of KP104 in Systemic Lupus Erythematosus, sponsored by Kira Pharmacenticals (US), LLC.. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Kira Pharmacenticals (US), LLC. · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns
Updated Nov 9, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KP104 in participants with systemic lupus erythematosus (SLE)-Thrombotic microangiopathy (TMA). The study consists of 2 parts: Part 1 (Dose Optimization) and Part 2 (Proof of Concept). All participants will receive KP104 in combination with standard of care (SOC) for SLE-TMA.

02

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic lupus erythematosus
  • Thrombotic microangiopathy
  • Dose Selection
  • Proof of Concept
  • KP-104
03

In context

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Kira Pharmacenticals (US), LLC. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for SLE per the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria.
  • Decrease in count to less than (\<)150,000/microliters (mcL).
  • Abnormal renal function.
  • Females of with negative pregnancy test and males must agree to practice effective from Screening until 28 days after the End of study (EOS) visit.
  • Willing and able to provide .
  • Evidence of microangiopathic hemolytic anemia

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other TMA syndromes.
  • A renal within 7 days of screening that shows exclusively chronic changes of TMA.
  • Positive Coombs test at the time of TMA diagnosis.
  • Active or unresolved Neisseria meningitidis infection at screening.

Only key inclusion and exclusion criteria have been included.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Optimization Cohort 1, Dose 1

    Participants will be administered with KP104 as a weekly maintenance dose for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the Internal Data Review Committee (IDRC) to determine Dosing Regimen 2

    Drug: KP104

  • Experimental
    Part 1: Dose Optimization Cohort 2, Dose 2

    Participants will be administered with KP104 dose regimen 2 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the IDRC to determine Dosing Regimen 3.

    Drug: KP104

  • Experimental
    Part 1: Dose Optimization Cohort 3, Dose 3

    Participants will be administered with KP104 dose regimen 3 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by IDRC to determine the Optimal biologic dose (OBD) for Part 2.

    Drug: KP104

  • Experimental
    Part 2: OBD Cohort, Dose 4

    Participants will be administered with KP104 OBD for 24 Weeks.

    Drug: KP104

Interventions

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Number of participants with Treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) and Adverse events of special interest (AESIs)

    Time frame: Up to 24 weeks

  2. Part 2: Percent change from Baseline in platelet count

    Time frame: Baseline (Day 1) and up to Week 12

  3. Part 2: Percent change from Baseline in serum lactate dehydrogenase (LDH) levels

    Time frame: Baseline (Day 1) and up to Week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2022
First posted
Aug 17, 2022
StartEst.
Mar 2025
Primary completionEst.
Mar 2026
CompletionEst.
Apr 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns
changed Nov 9, 2026
Enrollment
24 (estimated)→0 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Withdrawn
    Why stopped Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns
    Enrollment 24 (estimated)→0 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05504187
Lead sponsor
Kira Pharmacenticals (US), LLC.
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Mar 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vensobafusp alfa

Start the discussion